Something significant happened last month. On April 18, 2026, the President signed an executive order titled “Accelerating Medical Treatments for Serious Mental Illness.” For those of us who have spent years preparing the clinical workforce for this moment, this order can be taken as a policy signal of validation with real implications for how this field develops.
Within days, the FDA awarded Priority Review Vouchers to programs of research led by three organizations: Otsuka, Compass Pathways, and Usona Institute. These vouchers can significantly accelerate review timelines, and their distribution across commercial, academic, and nonprofit sectors reflects a broadening of federal commitment to moving specific products through the regulatory process.
What the Executive Order Actually Does
The order directs the FDA to prioritize psychedelic drugs with Breakthrough Therapy designation through the National Priority Voucher Program, instructs HHS to allocate at least $50 million from ARPA-H to support state-level programs, and calls for collaboration between HHS, FDA, and the Department of Veterans Affairs on clinical trial participation and data sharing. Critically, it directs the Attorney General to initiate and complete rescheduling review for any Schedule I substance that has successfully completed Phase 3 trials and received FDA approval.
That last provision matters enormously, and its implications extend further than most coverage has acknowledged. The obvious benefit is for patients: rescheduling removes the administrative gap between FDA approval and the point at which an approved drug can actually be prescribed. But rescheduling also directly accelerates the research pipeline. Schedule I status imposes significant costs and bureaucratic barriers on researchers, special DEA registration requirements, storage and handling restrictions, and institutional compliance burdens that add time and expense to every study. Once a drug moves off Schedule I, those constraints lift substantially, making it easier to conduct research, recruit sites, and keep the science moving forward.
The order also invokes the Right to Try Act as a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, before approval. This is significant for the ibogaine field in particular, where promising data on opioid withdrawal and addiction have long been constrained by the compound’s Schedule I status. The explicit mention of ibogaine reflects a broadening of federal attention beyond psilocybin and MDMA, and clinicians working in addiction treatment should take note.
On the ibogaine front, the FDA also cleared the first ibogaine-related Investigational New Drug application in conjunction with the order’s signing. The IND belongs to DemeRx, whose oral noribogaine candidate (DMX-1001) has been cleared to advance for the treatment of alcohol use disorder, beginning with an alcohol interaction trial and targeting a Phase 2 trial start in 2027. This opens a formal U.S. clinical pathway for a compound that has largely operated outside the domestic regulatory system. Researchers quoted in Psychedelic Alpha were careful to note that ibogaine remains at an early stage of development relative to psilocybin, and that rigorous science must accompany the current momentum, a caution worth holding alongside the genuine excitement.
Priority Review Vouchers: Who They Went To and Why It Matters
Compass Pathways’ COMP360 psilocybin for treatment-resistant depression now has two Phase 3 trials behind it, the second of which achieved its primary endpoint, as I noted in last month’s essay. A Priority Review Voucher applied to a future NDA filing could shave months off the review clock. Usona Institute has been running a Phase 3 trial of psilocybin for major depressive disorder under a nonprofit model committed to broad, low-cost access. Their inclusion is meaningful for the access and equity questions that have long mattered to thoughtful people in this field. Otsuka brings the commercial infrastructure that can support wide-scale deployment if and when approval arrives.
These are programs that will be familiar to anyone following the research closely. What is new is the federal imprimatur now attached to them, a signal to investors, health systems, payers, and workforce developers that these are the pathways worth building around.
What This Means for Your Career Planning
I have written in recent months about the importance of training now rather than waiting. This executive order and the accompanying voucher awards make that case more urgently than I can.
When FDA approval arrives, rescheduling, prescribing infrastructure, payer coverage, and clinical deployment follow in a sequence that has taken years for other novel psychiatric treatments. The order explicitly calls for rescheduling to happen “as quickly as practicable,” but that sequence still begins at approval, a foreseeable, near-term event that federal policy is now actively accelerating. Clinicians positioned to work in this field are those who have already built foundational competency. You cannot compress that preparation into the weeks after an approval announcement.
For clinicians in addiction treatment, the emphasis on ibogaine deserves specific attention. The Right to Try pathway, the ARPA-H funding, and the call for federal-state collaboration suggest ibogaine may move along a different and potentially faster track, one that does not follow a traditional commercial drug development path. The cardiac screening requirements, the necessity of comprehensive medical oversight, and the complexity of the introspective phases of ibogaine treatment mean this is a compound that demands serious preparation from any provider who engages with it.
On the Broader Context
Federal policy can move in unexpected directions. An executive order is a policy signal, and funding directed by executive action can be redirected. I am describing a direction, not a guarantee.
What I am saying is that the directional signal is now coming from multiple points simultaneously: late-stage clinical data, federal executive action, FDA administrative decisions, and growing investment in clinical infrastructure. When signals converge like this, the probability of clinical adoption rises substantially.
The executive order names something real about the scale of need. Over 14 million Americans have a serious mental illness, and drug overdose deaths have claimed more than 100,000 lives annually in recent years. Veteran suicide rates remain more than twice those of the general adult population. These numbers are familiar to anyone in mental health and addiction treatment. They are now the stated justification for federal prioritization of psychedelic treatments, which changes the political durability of this investment in ways that matter for the long term.
Looking Ahead
At Fluence, our job is to prepare clinicians for the world that is coming, one in which psychedelic treatments will be available within the healthcare system, with all the demands and responsibilities that entails. That means clinicians who understand screening and contraindications, who can guide preparation conversations without projecting onto a patient’s experience, who can support altered-state sessions with steadiness and skill, and who treat integration as the phase in which lasting change is most likely to take root.
None of that comes from reading a policy brief. It comes from careful, sustained, community-supported training. That is what we are here to provide, and why the work we are doing together now matters as much as it ever has.
Thanks for reading,
Fluence Co-Founder
The revised version of our Introduction to KAP Bundle reflects the latest advancements in the field, incorporating updated competency frameworks, refined learning objectives, and new recommendations for ethically grounded, clinically effective practice. As the evidence base and professional standards around ketamine-assisted psychotherapy continue to evolve, so does our commitment to ensuring that practitioners have access to training that keeps pace with them. Whether you are new to the modality or returning to strengthen your foundation, this updated course offers a current, rigorous, and practically oriented entry point into one of today's most promising approaches to mental health care.
Lisa Wang is a psychiatrist and psychotherapist based in New York and New Jersey. She takes an integrative approach to treatment that incorporates psychotherapy, psychopharmacology, and recommending other complementary treatment modalities as indicated. She is trained as a psilocybin therapist through Compass Pathways and has been a lead therapist on studies of psilocybin for treatment resistant depression and body dysmorphic disorder at New York State Psychiatric Institute. She is also a site physician for the MAPS-sponsored Phase 3 Clinical Trials of MDMA-Assisted Psychotherapy for PTSD. She has trained in a number of psychotherapy modalities including psychodynamic psychotherapy, cognitive behavioral therapy, dialectical behavior therapy, interpersonal psychotherapy, and psychedelic integration. She also aspires to bring her experience from the cushion as a meditator to all aspects of her work.
Lisa’s expertise is featured extensively in our updated Introduction to Ketamine-Assisted Therapy Bundle course. Keep an eye out for that, it will be released in the coming months.
We are excited to offer a webinar in partnership with the Psychotherapy Networker this May 11th, at 1pm, EDT. Our Founder and CEO, Elizabeth Nielson will join their team to discuss how psychedelic therapy is moving closer to mainstream mental health care.
If your patients are already asking about psychedelic therapy, this conversation will help you answer with more clarity and less guesswork. You’ll leave with a realistic picture of what may be coming, what remains uncertain, and how to position your practice wisely in a rapidly changing field.
Webinar attendees will receive a coupon for a free 1-hour CE-granting course from Fluence.
Curious about training in psychedelic therapy but unsure where to begin?
We’d love to help you gain clarity on how one of our courses fits into your path. Schedule a free 1-on-1 Zoom call with Kabir Cooppan-Boyd, dedicated to guiding you on your learning journey.
During your call, Kabir can answer your questions and explain how our courses connect to professional certificates in:
Psilocybin Facilitation
Ketamine-Assisted Psychotherapy
Psychedelic Harm Reduction and Integration
If you’re a clinician with questions or curiosity about our programs, this personalized conversation is the perfect way to find your best next step.
Schedule your free 1-on-1 Zoom call with Kabir
Start your journey now and move toward certification in Psilocybin Facilitation, Ketamine-Assisted Psychotherapy, or Psychedelic Harm Reduction and Integration at the current, lower rate.
All certificate programs start with our six-week Essentials of Psychedelic Therapy course, with the July cohort taught by Sarah Zoghbi, LPC.
Certificate Programs
Psilocybin Facilitation
July 15, 2026 - March 21, 2027
Ketamine-Assisted Psychotherapy
July 15 - Nov 24, 2026
All Fluence alumni who have taken a live-online course are eligible to join our 1200+ person Google Group. Members can work through protocol questions, share what they are seeing in the field, and get perspectives from colleagues doing the same work. If you have taken a live-online course but have not received your invite to the group, reach out here:
Email info@fluencetraining.com
Trump Signs Order to Accelerate Access to Psychedelic Drug Treatments
President Trump’s executive order directs federal agencies to speed up research, funding, and regulatory pathways for psychedelic therapies, particularly for serious mental illness and veteran care. It also signals a broader federal shift toward legitimizing psychedelic-assisted treatment within medical frameworks.
What a New Federal Green Light Means for Psychedelic Research
Axios examines how expedited FDA pathways could reshape the next phase of psychedelic research and commercialization, while emphasizing that clinician training and care infrastructure remain major bottlenecks.
Psychedelics as a Potential Treatment for Borderline Personality Disorder
This April publication explores emerging clinical trial designs using MDMA and related compounds for borderline personality disorder, including early-stage open-label work. It highlights both the promise of emotional processing interventions and the complexity of applying psychedelic therapy to high-risk populations.
